Clinical Trials Logo

PMF clinical trials

View clinical trials related to PMF.

Filter by:
  • None
  • Page 1

NCT ID: NCT06343805 Not yet recruiting - Clinical trials for Primary Myelofibrosis

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Start date: July 15, 2024
Phase: Phase 1
Study type: Interventional

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II JAK2 inhibitor, AJ1-11095, in subjects with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.

NCT ID: NCT04283526 Withdrawn - Myelofibrosis Clinical Trials

Study of Select Combinations in Adults With Myelofibrosis

Start date: November 30, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety, pharmacokinetics (PK) and preliminary efficacy of both the combination of MBG453 and NIS793 with or without decitabine or spartalizumab as well as single agent MBG453 and/or NIS793 single agent in myelofibrosis (MF) subjects post treatment with a Janus Kinase (JAK) inhibitor. In this study, combination therapies with novel agents including immune therapy will focus on determining the promising combinations that provide acceptable safety and efficacy independent of JAK inhibitors. Immune therapy combinations, such as MBG453 in combination with NIS793, might offer the potential to target MF across genetic heterogeneity. The primary objective of this study is to characterize the safety, tolerability and recomended dose for each treatment combination (MBG453 + NIS793, MBG453 + NIS793 + decitabine, and MBG453 + NIS793 + spartalizumab)

NCT ID: NCT01644110 Active, not recruiting - Clinical trials for Primary Myelofibrosis

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

POMINC
Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.